<DOC>
	<DOCNO>NCT00191737</DOCNO>
	<brief_summary>A single arm , open-label , phase 3 multicenter study evaluate effectiveness tolerability atomoxetine ( give daily , target dose 1.2 mg/kg/day ) , perceive patient , parent physician , impact self-esteem adolescent ( age 12 17 year ) Attention-Deficit/Hyperactivity Disorder treat outpatient Germany . An 8-week treatment phase follow 16-week extension period .</brief_summary>
	<brief_title>An Open-Label Study Atomoxetine Adolescents With Attention-Deficit/Hyperactivity Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Male female outpatient least 12 year age reach 18th birthday Diagnosis ADHD Normal intelligence Weigh le 30 kg 85 kg study entry Other relevant psychiatric diagnosis Are serious suicidal risk determine investigator Have history severe allergy Alcohol drug abuse within past 3 month Are female patient pregnant breastfeeding . Sexually active female must use medically acceptable method contraception .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>